Q1 Earnings Estimate for Novartis Issued By Zacks Research

Novartis AG (NYSE:NVS) – Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for shares of Novartis in a research note issued to investors on Monday, December 15th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $2.26 for the quarter, down from their previous estimate of $2.27. The consensus estimate for Novartis’ current full-year earnings is $8.45 per share. Zacks Research also issued estimates for Novartis’ Q4 2026 earnings at $2.04 EPS, FY2026 earnings at $9.22 EPS, Q3 2027 earnings at $2.46 EPS and FY2027 earnings at $10.16 EPS.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 28th. The company reported $2.25 EPS for the quarter, missing analysts’ consensus estimates of $2.26 by ($0.01). The firm had revenue of $14.36 billion during the quarter, compared to analyst estimates of $13.70 billion. Novartis had a net margin of 26.49% and a return on equity of 41.21%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.06 earnings per share.

Several other research firms have also issued reports on NVS. Wall Street Zen raised shares of Novartis from a “hold” rating to a “buy” rating in a research report on Friday, November 28th. Morgan Stanley restated an “overweight” rating on shares of Novartis in a research report on Wednesday, December 3rd. The Goldman Sachs Group reiterated a “sell” rating and issued a $118.00 price target (down from $119.00) on shares of Novartis in a research report on Friday, September 12th. Jefferies Financial Group restated a “hold” rating on shares of Novartis in a research note on Monday, October 27th. Finally, Cfra set a $126.00 target price on shares of Novartis and gave the stock a “hold” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $119.75.

Novartis Price Performance

NYSE:NVS opened at $134.96 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.68 and a current ratio of 0.88. The company has a 50-day moving average of $129.53 and a 200-day moving average of $124.45. Novartis has a 52 week low of $96.06 and a 52 week high of $136.66. The company has a market capitalization of $285.09 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 1.91 and a beta of 0.52.

Hedge Funds Weigh In On Novartis

Several large investors have recently made changes to their positions in the company. Keybank National Association OH increased its position in Novartis by 13.2% in the 2nd quarter. Keybank National Association OH now owns 49,377 shares of the company’s stock valued at $5,975,000 after acquiring an additional 5,742 shares during the period. Sonora Investment Management Group LLC acquired a new stake in Novartis in the second quarter valued at $266,000. Cypress Capital Group raised its position in Novartis by 84.1% during the 2nd quarter. Cypress Capital Group now owns 5,776 shares of the company’s stock worth $699,000 after purchasing an additional 2,638 shares during the last quarter. Focus Partners Wealth lifted its holdings in Novartis by 16.8% during the 1st quarter. Focus Partners Wealth now owns 47,548 shares of the company’s stock worth $5,311,000 after buying an additional 6,849 shares during the period. Finally, Marshall Financial Group LLC bought a new stake in shares of Novartis in the 2nd quarter valued at about $1,909,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.